The birth of therapy with cultured cells
The birth of therapy with cultured cells
复制标题
DOI：
10.1002/bies.20797
复制
发表时间：
2008-09-01
期刊：
影响因子：
4
通讯作者：
Green, Howard
中科院分区：
文献类型：
--
作者：
Green, Howard
很久以前，我开始着手解决一个问题，但沿着发生了一件事：我被一个意想不到的观察所转移。此后，我的研究方向在每一个阶段都是通过不断熟悉实验材料和可以用它做什么来指导的。结果是培养角质形成细胞治疗的诞生。随后的发展很快导致了生物表面技术公司的成立（后来被Genzyme公司收购），该公司为世界许多地区的烧伤患者提供自体培养物。其他人的进一步进展导致了培养的角质形成细胞的新的治疗应用，例如治疗眼部疾病和基因治疗。不幸的是，已经出现了严重的监管问题，对未来的进展构成威胁。正如在这段简短的历史中所描述的，用于治疗人类疾病的细胞疗法的最初发展阶段是可能的，因为没有委员会或政府法规的限制。
Long ago, I set out to solve a problem, but something happened along the way: I was diverted by an unexpected observation. Thereafter, the direction of my research was guided at each stage by increasing familiarity with the experimental material and what could be done with it. The result was the birth of therapy with cultured keratinocytes. Subsequent developments soon led to the formation of the company Biosurface Technology (later taken over by the Genzyme Corporation), which provided autologous cultures for burn victims in many parts of the world. Further progress by others led to new therapeutic applications of cultured keratinocytes, such as treatment of an ocular disease and gene therapy. Unfortunately, there have developed serious regulatory problems that are a danger to future progress. As described in this brief history, the initial stages of development of cell therapy for the treatment of human disease were possible only because there was no restraint by committees or governmental regulations.